Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guarneri

Showing results (1351-1360 of 1,433) with videos related to

Pageof 144
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 studyValentina Guarneri, Franco Bassan, Vittorina Zagonel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Cancer Treatment Reviews|January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisFrancesco Schettini, Tomás Pascual, Benedetta Conte, et al.
The American Journal of Gastroenterology|May 29, 2019
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL ExperienceVincenza Calvaruso, Irene Cacciola, Anna Licata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Contact Dermatitis|November 21, 2019
A survey of members of the European Surveillance System on Contact Allergy and the EU project "StanDerm" to identify allergens tested in cosmetic series across EuropeEmma Horton, Mark Wilkinson, Kristiina Aalto-Korte, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2020
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life studyC Patruno, M Napolitano, G Argenziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Dermatology and Therapy|February 19, 2026
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE StudyEmanuele Trovato, Claudio Bonifati, Simone Ribero, et al.
Pageof 144

Showing results (1351-1360 of 1,433) with videos related to

Sort By:
Pageof 144
European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 studyValentina Guarneri, Franco Bassan, Vittorina Zagonel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Cancer Treatment Reviews|January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisFrancesco Schettini, Tomás Pascual, Benedetta Conte, et al.
The American Journal of Gastroenterology|May 29, 2019
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL ExperienceVincenza Calvaruso, Irene Cacciola, Anna Licata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Contact Dermatitis|November 21, 2019
A survey of members of the European Surveillance System on Contact Allergy and the EU project "StanDerm" to identify allergens tested in cosmetic series across EuropeEmma Horton, Mark Wilkinson, Kristiina Aalto-Korte, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2020
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life studyC Patruno, M Napolitano, G Argenziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Dermatology and Therapy|February 19, 2026
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE StudyEmanuele Trovato, Claudio Bonifati, Simone Ribero, et al.
Pageof 144